On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW to Propose Two-Third Sampling Rate for Wholesaler Survey for Off-Year Drug Re-Pricing; Go/No-Go Debate to Continue
June 16, 2020
- MHLW Starts Inviting Coronavirus Vaccine Developers after 2nd Extra Budget Passed
June 15, 2020
- MHLW to Allow Blood Collection for Use of Blood in Drug R&D under Amended Blood Law
June 12, 2020
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
- LDP Study Group Calls for Postponing Off-Year Re-Pricing
June 9, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- JPMA Urges Govt to Establish “Headquarters” for Infectious Disease Control Policy: Chief
June 9, 2020
- MHLW Grants Orphan Status to 8 APIs
June 8, 2020
- Minister Mentions First Half 2021 Goal for Coronavirus Vaccination Start
June 8, 2020
- ASEAN + 3 Ministers Vow to Work towards Smooth Drug Distribution amid COVID-19
June 8, 2020
- Saliva-Based COVID-19 PCR Tests Reimbursed for Cases within 9 Days of First Symptoms: MHLW
June 4, 2020
- Japan Eyes Coronavirus Vaccination Launch in First Half of 2021
June 3, 2020
- Label Updates Ordered for Uptravi, Plavix, Permitting Their Concomitant Use: MHLW
June 3, 2020
- Japan OKs Add’l Indications for Ofev, Xtandi/Erleada and More
June 1, 2020
- Oral Semaglutide Clears MHLW Panel, Now in Line for June Approval
June 1, 2020
- MHLW Panel Gives Blessing to 1st Triple Combo Therapy for Asthma; Humira Biosimilar Also in Line for June OK
May 29, 2020
- Japan Sets 30 Day Prescription Limit for Shionogi’s ADHD Med Vyvanse
May 29, 2020
- 145.5 Billion Yen Allocated for COVID-19 Vaccine Production in Second Extra Budget: MHLW
May 29, 2020
- GSK’s Cost-Effectiveness Analysis for Trelegy Delayed, First Product under Full CEA Scheme
May 28, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…